Mittemeyer Bernhard 4

Accession 0001140361-10-050279

CIK 0001301348other

View on SEC.gov Company Profile

Filed

Dec 16, 7:00 PM ET

Accepted

Dec 17, 4:15 PM ET

Size

29.2 KB

Accession

0001140361-10-050279

Insider Transaction Report

Form 4

Period: 2010-12-13

HEMOBIOTECH, INC.HMBT.OB

Mittemeyer Bernhard

Director

Transactions

Award
Options to Purchase Common Stock
2009-09-25+7,000→ 144,582 total
Exercise: $0.27From: 2009-09-25Exp: 2019-09-25→ Common Stock (7,000 underlying)
Award
Options to Purchase Common Stock
2010-03-26+7,000→ 193,582 total
Exercise: $0.51From: 2010-03-26Exp: 2020-03-26→ Common Stock (7,000 underlying)
Award
Options to Purchase Common Stock
2010-06-25+15,000→ 227,582 total
Exercise: $0.40From: 2010-06-25Exp: 2020-06-25→ Common Stock (15,000 underlying)
Award
Options to Purchase Common Stock
2010-09-24+7,000→ 234,582 total
Exercise: $0.30From: 2010-09-24Exp: 2020-09-24→ Common Stock (7,000 underlying)
Award
Options to Purchase Common Stock
2009-12-24+7,000→ 174,582 total
Exercise: $0.50From: 2009-12-24Exp: 2019-12-24→ Common Stock (7,000 underlying)
Award
Options to Purchase Common Stock
2010-03-26+12,000→ 205,582 total
Exercise: $0.51From: 2010-03-26Exp: 2020-03-26→ Common Stock (12,000 underlying)
Award
Options to Purchase Common Stock
2010-06-25+7,000→ 212,582 total
Exercise: $0.40From: 2010-06-25Exp: 2020-06-25→ Common Stock (7,000 underlying)
Award
Options to Purchase Common Stock
2010-09-24+19,000→ 253,582 total
Exercise: $0.30From: 2010-09-24Exp: 2020-09-24→ Common Stock (19,000 underlying)
Award
Options to Purchase Common Stock
2009-10-31+23,000→ 167,582 total
Exercise: $0.25From: 2009-10-31Exp: 2019-10-31→ Common Stock (23,000 underlying)
Award
Options to Purchase Common Stock
2009-12-31+12,000→ 186,582 total
Exercise: $0.31From: 2009-12-31Exp: 2019-12-31→ Common Stock (12,000 underlying)

Footnotes (12)

[F1]From October 31, 2009 through September 30, 2010, the board of directors received additional options in lieu of their quarterly compensation. These options are immediately vested and exercisable upon issuance.
[F10]The Options to Purchase Common Stock were granted on June 25, 2010. All Options are immediately vested and exercisable upon issuance.
[F11]The Options to Purchase Common Stock were granted on September 24, 2010. All Options are immediately vested and exercisable upon issuance.
[F12]The Options to Purchase Common Stock were granted on September 24, 2010. All Options are immediately vested and exercisable upon issuance.
[F2]On November 18, 2010, the board of directors of HemoBioTech, Inc. agreed to reprice all options to $.25.
[F3]The Options to Purchase Common Stock were granted on September 25, 2009. All Options are immediately vested and exercisable upon issuance.
[F4]The Options to Purchase Common Stock were granted on October 31, 2009. All Options are immediately vested and exercisable upon issuance.
[F5]The Options to Purchase Common Stock were granted on December 24, 2009. All Options are immediately vested and exercisable upon issuance.
[F6]The Options to Purchase Common Stock were granted on December 31, 2009. All Options are immediately vested and exercisable upon issuance.
[F7]The Options to Purchase Common Stock were granted on March 26, 2010. All Options are immediately vested and exercisable upon issuance.
[F8]The Options to Purchase Common Stock were granted on March 26, 2010. All Options are immediately vested and exercisable upon issuance.
[F9]The Options to Purchase Common Stock were granted on June 25, 2010. All Options are immediately vested and exercisable upon issuance.

Documents

1 file

4
doc1.xmlPrimary
FORM 4

Issuer

HEMOBIOTECH, INC.

CIK 0001301348

→

Entity typeother

Related Parties

filerCIK 0001329093

Filing Metadata

Form type: 4
Filed: Dec 16, 7:00 PM ET
Accepted: Dec 17, 4:15 PM ET
Size: 29.2 KB

View on SEC.gov